[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520391":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":117,"collaborators":31,"id":119,"slug":31,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":120,"sex":126,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":31,"studyType":132,"phases":133,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":60,"whyStopped":31,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},{"fullName":5,"class":6},"UCB Pharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Zilucoplan Arm","EXPERIMENTAL","Study participants will receive zilucoplan in pre-defined dose based on their weight.",[13],"Drug: Zilucoplan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Zilucoplan","Zilucoplan will be administered subcutaneously to pediatric study participants.",[9],[21],"RA101495",[23],{"name":24,"affiliation":25,"role":26},"UCB Cares","001 844 599 2273","STUDY_DIRECTOR",[28,33],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","+18445992273 (USA)",null,"ucbcares@ucb.com",{"name":24,"role":29,"phone":25,"phoneExt":31,"email":31},[35,48,58,68,77,86,95,100,109],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":31},"Mg0014 50168","WITHDRAWN","Chicago","Illinois","60611","United States",{"type":43,"coordinates":44},"Point",[45,46],-87.65005,41.85003,{"lat":46,"lon":45},{"facility":49,"status":37,"city":50,"state":51,"zip":52,"country":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":31},"Mg0014 50574","Denton","Texas","76208",{"type":43,"coordinates":54},[55,56],-97.13307,33.21484,{"lat":56,"lon":55},{"facility":59,"status":60,"city":61,"state":31,"zip":31,"country":62,"cosmosGeoPoint":63,"geoPoint":67,"contacts":31},"Mg0014 40144","RECRUITING","Milan","Italy",{"type":43,"coordinates":64},[65,66],12.59836,42.78235,{"lat":66,"lon":65},{"facility":69,"status":60,"city":70,"state":31,"zip":31,"country":71,"cosmosGeoPoint":72,"geoPoint":76,"contacts":31},"Mg0014 40774","Katowice","Poland",{"type":43,"coordinates":73},[74,75],19.02173,50.2597,{"lat":75,"lon":74},{"facility":78,"status":79,"city":80,"state":31,"zip":31,"country":71,"cosmosGeoPoint":81,"geoPoint":85,"contacts":31},"Mg0014 40218","ACTIVE_NOT_RECRUITING","Warsaw",{"type":43,"coordinates":82},[83,84],21.01178,52.22977,{"lat":84,"lon":83},{"facility":87,"status":60,"city":88,"state":31,"zip":31,"country":89,"cosmosGeoPoint":90,"geoPoint":94,"contacts":31},"Mg0014 20104","Seoul","South Korea",{"type":43,"coordinates":91},[92,93],126.9784,37.566,{"lat":93,"lon":92},{"facility":96,"status":60,"city":88,"state":31,"zip":31,"country":89,"cosmosGeoPoint":97,"geoPoint":99,"contacts":31},"Mg0014 20220",{"type":43,"coordinates":98},[92,93],{"lat":93,"lon":92},{"facility":101,"status":60,"city":102,"state":31,"zip":31,"country":103,"cosmosGeoPoint":104,"geoPoint":108,"contacts":31},"Mg0014 40735","Glasgow","United Kingdom",{"type":43,"coordinates":105},[106,107],-4.25763,55.86515,{"lat":107,"lon":106},{"facility":110,"status":60,"city":111,"state":31,"zip":31,"country":103,"cosmosGeoPoint":112,"geoPoint":116,"contacts":31},"Mg0014 40736","London",{"type":43,"coordinates":113},[114,115],-0.12574,51.50853,{"lat":115,"lon":114},{"type":118,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100520391",false,"NCT06055959","A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis","ziMyG","Inclusion Criteria:\n\nUnited States of America (USA) specific inclusion criterion:\n\n\\- Participant must be 12 to \\\u003C18 years of age at the time of signing the Informed consent\u002Fassent according to local regulation\n\nRest of world (ROW) specific inclusion criterion:\n\n\\- Participant must be 2 to \\\u003C18 years of age at the time of signing the Informed consent\u002Fassent according to local regulation\n\nGlobal inclusion criteria:\n\n* Participant has a diagnosis of generalized myasthenia gravis (gMG) confirmed by a prior positive serologic test result to acetylcholine receptor (AChR) prior to Screening\n* Participant meets the criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening\n* Participants with gMG, including:\n* An MG-activities of daily living (MG-ADL) total score of 6 or more in adolescents from 12 years to \\\u003C18 years of age at Screening\n* Documented weakness in at least 1 limb, neck, or bulbar muscle in children from 2 years to \\\u003C12 years of age at Screening (does not apply to US)\n* Documented vaccination against meningococcal infections within 3 years prior to study start. If not fully vaccinated, participants must receive appropriate prophylactic antibiotic treatment until at least 2 weeks after the initial dose of vaccine(s)\n\nExclusion Criteria:\n\n* Participant has known positive serology for muscle-specific kinase\n* Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study\n* Participant has had a thymectomy within 6 months prior to Baseline\n* Participant has minimal Manifestation Status of MG based on the clinical judgement of the Investigator\n* Current or recent systemic infection within 2 weeks prior to Baseline or infection requiring intravenous antibiotics within 4 weeks prior to Baseline","ALL","12 Years","17 Years",{"count":130,"type":131},8,"ESTIMATED","INTERVENTIONAL",[134,135],"PHASE2","PHASE3","The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).",[138],"Generalized Myasthenia Gravis",[21,140,141,142,143,144],"gMG","generalized myasthenia gravis","zilucoplan","pediatric","MG0014","2026-05-07",{"date":147,"type":148},"2026-05-08","ACTUAL",{"date":150,"type":148},"2024-10-16",{"date":152,"type":131},"2026-12-25",{"name":154,"class":6},"UCB Biopharma SRL",9]